COPD and Asthma Devices Market Size, Share and Growth Outlook, 2026

COPD and Asthma Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global COPD and Asthma Devices Market size is forecast to increase from $51.11 Billion in 2026 to $73.24 Billion in 2034 at a CAGR of 4.6% between 2026 and 2034.

The COPD and Asthma Devices market report provides detailed analysis and outlook of COPD and Asthma Devices segments including By Product Type: (Inhalers, Nebulizers, Oxygen Delivery Systems, Peak Flow Meters, Spacer Devices), By Indication: (Asthma, Chronic Obstructive Pulmonary Disease ), By Mode of Operation: (Conventional Devices, Digital), By Age Group: (Pediatric, Adult, Geriatric), By End-User: (Hospitals and Clinics, Home Healthcare, Ambulatory Surgical Centers, Pulmonary Rehabilitation Centers, Retail Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

COPD and Asthma Devices Industry Overview

Smart Inhaler Technologies Advancing Respiratory Disease Management

The COPD and asthma devices industry is increasingly focused on integrating digital health capabilities into respiratory care solutions to improve treatment adherence and long-term disease management. A significant development in this area is the expansion of a digital health partnership by AstraZeneca PLC aimed at incorporating smart sensor technology into pressurized metered-dose inhalers (pMDIs). These advanced sensors monitor both medication adherence and inhalation technique, generating real-time data that can be shared with patients and healthcare providers. By providing actionable insights into inhaler usage patterns, smart inhaler technologies support improved disease control and help address one of the most persistent challenges in respiratory care: inconsistent treatment adherence. The growing adoption of connected inhaler platforms reflects the broader movement toward personalized, data-driven management of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Home-Based Respiratory Support Driving Innovation in Non-Invasive Ventilation

The COPD and asthma devices industry is also benefiting from increasing demand for home-based respiratory therapies that improve patient convenience and quality of life. ResMed Inc. introduced a new generation of portable non-invasive ventilation (NIV) devices specifically designed for home management of COPD patients. These systems incorporate enhanced connectivity features and ultra-quiet motor technology to improve patient comfort and facilitate long-term therapy adherence. The shift toward portable and connected respiratory support solutions aligns with broader healthcare trends emphasizing decentralized care, remote monitoring, and home-based disease management. As healthcare providers seek to reduce hospitalizations and support chronic disease management outside traditional clinical settings, advanced NIV devices are becoming increasingly important components of comprehensive respiratory care programs.

Precision Diagnostics Supporting Personalized Device Utilization

Clinical guidelines are playing an increasingly influential role in shaping device utilization strategies within the COPD and asthma devices industry. The updated strategy document from the Global Initiative for Chronic Obstructive Lung Disease places greater emphasis on objective diagnostic tools such as spirometry and fractional exhaled nitric oxide (FeNO) testing to guide treatment decisions and optimize device selection. These diagnostic approaches enable clinicians to tailor respiratory therapies according to individual patient characteristics, disease severity, and inflammatory profiles. The growing focus on precision medicine in respiratory care is encouraging the integration of diagnostic data with therapeutic device selection, helping improve treatment outcomes and resource utilization. As personalized disease management becomes increasingly important, manufacturers are developing respiratory devices that can operate within broader digital health ecosystems designed to support individualized asthma and COPD care pathways.

COPD and Asthma Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global COPD and Asthma Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- AstraZeneca plc, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc (GSK), Philips Healthcare, Medtronic plc, Getinge AB, 3M Company (Drug Delivery Systems), Teleflex Incorporated, Cipla Inc., Teva Pharmaceutical Industries Ltd.. The COPD and Asthma Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the COPD and Asthma Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth COPD and Asthma Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by COPD and Asthma Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional COPD and Asthma Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

COPD and Asthma Devices Market Competitive Benchmarking and Company Analysis

Leading companies in COPD and Asthma Devices industry include- AstraZeneca plc, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc (GSK), Philips Healthcare, Medtronic plc, Getinge AB, 3M Company (Drug Delivery Systems), Teleflex Incorporated, Cipla Inc., Teva Pharmaceutical Industries Ltd.. The COPD and Asthma Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US COPD and Asthma Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the COPD and Asthma Devices market remains one of the strongest-performing segments in the country.
The US COPD and Asthma Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US COPD and Asthma Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across COPD and Asthma Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian COPD and Asthma Devices markets

Canada's strong COPD and Asthma Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian COPD and Asthma Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany COPD and Asthma Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest COPD and Asthma Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of COPD and Asthma Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany COPD and Asthma Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the COPD and Asthma Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support COPD and Asthma Devices sales through 2034

France COPD and Asthma Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK COPD and Asthma Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of COPD and Asthma Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China COPD and Asthma Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China COPD and Asthma Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of COPD and Asthma Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese COPD and Asthma Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India COPD and Asthma Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian COPD and Asthma Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil COPD and Asthma Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa COPD and Asthma Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

COPD and Asthma Devices Market Segmentation

By Product Type:
Inhalers
Nebulizers
Oxygen Delivery Systems
Peak Flow Meters
Spacer Devices
By Indication:
Asthma
Chronic Obstructive Pulmonary Disease
By Mode of Operation:
Conventional Devices
Digital
By Age Group:
Pediatric
Adult
Geriatric
By End-User:
Hospitals and Clinics
Home Healthcare
Ambulatory Surgical Centers
Pulmonary Rehabilitation Centers
Retail Pharmacies

Top Companies in COPD and Asthma Devices Industry

AstraZeneca plc
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc (GSK)
Philips Healthcare
Medtronic plc
Getinge AB
3M Company (Drug Delivery Systems)
Teleflex Incorporated
Cipla Inc.
Teva Pharmaceutical Industries Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025